This post is from a suggested group
Fibroscan: Non-Invasive Technology for Liver Disease Assessment and Fibrosis Evaluation
Fibroscan is a non-invasive medical device that assesses liver stiffness and fibrosis using transient elastography. It is widely used in patients with chronic liver diseases such as hepatitis B, hepatitis C, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. By emitting low-frequency vibrations and ultrasound waves, Fibroscan measures liver elasticity, providing a quantitative score indicative of fibrosis severity.
Fibroscan offers advantages over liver biopsy, including painless procedure, immediate results, repeatability, and lower risk of complications. It supports early detection, monitoring disease progression, evaluating treatment response, and guiding clinical decision-making. Technological advancements include controlled attenuation parameter (CAP) for assessing liver steatosis and portable Fibroscan devices for use in outpatient or field settings. Fibroscan has become a standard non-invasive alternative to liver biopsy, improving patient compliance and enabling population-level liver disease management.